Patient-Oriented Evidence That Matters

Fewer Subsequent Strokes with Ticagrelor Plus Aspirin than with Aspirin Alone


Am Fam Physician. 2021 Feb 15;103(4):249.

Clinical Question

Is ticagrelor (Brilinta) plus aspirin superior to aspirin alone for decreasing the risk of subsequent stroke or death in patients with acute ischemic stroke?

Bottom Line

For patients with mild to moderate acute nonembolic ischemic stroke, treatment with ticagrelor plus aspirin for 30 days resulted in fewer subsequent strokes but similar overall disability and an increase in severe bleeding compared with aspirin alone (number needed to treat to prevent one event of the composite outcome of stroke or death = 92; number needed to harm to cause one episode of severe bleeding = 263). (Level of Evidence = 1b)


Although a previous study of ticagrelor did not show a benefit over aspirin in patients with acute ischemic stroke, the effect of ticagrelor plus aspirin is not known. Using concealed allocation, the investigators randomized patients with mild to moderate acute nonembolic ischemic strokes (National Institutes of Health Stroke Scale score less than 5) or high-risk transient ischemic attacks to receive ticagrelor plus aspirin (n = 5,523) or matching placebo plus aspirin (n = 5,493). Patients receiving thrombolysis or thrombectomy and those who had intracranial bleeding were excluded. Ticagrelor (or matching placebo) was given at a loading dose of 180 mg, followed by a maintenance dosage of 90 mg twice daily for 30 days. Aspirin was given at a loading dose of 300 mg to 325 mg, followed by a dosage of 75 mg to 100 mg daily. The two groups were balanced at baseline: mean age was 65 years, 39% were women, and 91% presented with ischemic stroke. The primary outcome, a composite of subsequent stroke or death at 30 days, occurred less often in the ticagrelor plus aspirin group than in the aspirin-only group (5.5% vs. 6.6%; hazard ratio [HR] = 0.83; 95% CI, 0.71 to 0.96; P = .02). The secondary outcome of subsequent strokes was decreased from 6.3% to 5.0% in the ticagrelor plus aspirin group (HR = 0.79; 95% CI, 0.68 to 0.93; P = .004). Disability at the end of the treatment

POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.

For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.

To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.

This series is coordinated by Sumi Sexton, MD, editor-in-chief.

A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.



Want to use this article elsewhere? Get Permissions

More in AFP

Editor's Collections

Related Content

More in Pubmed


May 2022

Access the latest issue of American Family Physician

Read the Issue

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article